Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other financing activities (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Other financing activities for 2 consecutive years, with -$2.7 million as the latest value for Q3 2025.

  • Quarterly Other financing activities fell 491.32% to -$2.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Sep 2025, changed N/A year-over-year, with the annual reading at $2.6 million for FY2020, N/A changed from the prior year.
  • Other financing activities hit -$2.7 million in Q3 2025 for ARS Pharmaceuticals, down from $2.7 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.7 million in Q2 2025 to a low of -$2.7 million in Q3 2025.